AIM ImmunoTech progresses into NCI-funded Phase 2 study of product candidate Ampligen in melanoma

AIM ImmunoTech Inc (NYSE:AIM) CEO Thomas Equels joined Proactive’s Stephen Gunnion after the company announced the start of an NCI-funded Phase 2 study of its product candidate Ampligen in melanoma.

Equels gave an overview of Ampligen and explained the process for the Phase 2 study and the steps AIM will take if it is successful.

He also provided an overview of the AIM’s other programs with Ampligen.

#ProactiveInvestors #AIMImmunoTech #Ampligen #NYSE

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews